Resources

Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C

Showing 41 to 50 of 300 resources

  • Detecting & managing hepatitis C in primary care: Overcoming barriers to testing and treatment
    This short film, aimed at GPs and others working with primary care, looks at identifying those at risk of hepatitis C, through assessment & screening; testing and diagnosis, supported with practice examples.
    UK Apr 2015 Training, Tools & Templates Video
  • Detecting & managing hepatitis C in primary care: Supporting people through treatment
    This short film, aimed at GPs and others working in primary care, examines the support needs of people living with, and being treated for hepatitis C, the management of side effects, the promotion of harm reduction and positive lifestyle advice and the significance of integrated care and support for patients and carers.
    UK Apr 2015 Training, Tools & Templates Video
  • Detecting & managing hepatitis C in primary care: The impact and consequences of hepatitis C infection
    This short film, aimed at GPs and others working with primary care, covers the prevalence of undiagnosed hepatitis C, the growing public health burden of infection and the natural history and consequences of hepatitis C infection.
    UK Apr 2015 Training, Tools & Templates Video
  • Diagnosing viral hepatitis in the community: A 3-month pharmacy testing pilot
    This document sets out the findings of a 3 month pharmacy testing pilot.
    England Jan 2010 Case study, Reports & Research PDF
  • Divided Nations: Tackling the hepatitis C challenge across the UK
    In response to the public health challenge of Hepatitis C, national Governments in England, Scotland and Wales have taken radically different approaches. The All-Party Parliamentary Hepatology Group convened a meeting to explore the impact of the different national strategies. The meeting provided an opportunity for Parliamentarians, experts and stakeholders to compare and contrast the effectiveness of each approach and identify areas of best practice, which can be shared across national borders.
    UK Nov 2008 Reports & Research PDF
  • Drug-related infectious diseases in Europe
    This report provides an update on infectious diseases related to drug use in Europe for the period up to June 2016. It covers the most recent data both on infectious diseases among people who inject drugs in Europe, collected with the European Monitoring Centre for Drugs and Drug Addiction Drug-related infectious diseases (DRID) indicator, and on the responses in the area. It includes highlights and new findings discussed during the DRID indicator’s annual expert meeting, held in Lisbon on 6–8 June 2016.
    Rest of World Reports & Research PDF
  • EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
    These EASL Clinical Practice Guidelines (CPGs) are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that are approved at the time of their publication.
    UK, Rest of World 2014 Training, Reports & Research, Tools & Templates PDF
  • EASL Recommendations on Treatment of Hepatitis C 2016
    These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the current optimal management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved by the European Medicines Agency and other national European agencies at the time of their publication.
    Rest of World Sep 2016 Other, Reports & Research PDF
  • EASL Recommendations on Treatment of Hepatitis C: 2014
    These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decisionmaking process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that will be approved within less than 6 months at the time of their publication.
    UK Apr 2014 Reports & Research, Tools & Templates, Strategy & Planning PDF
  • East Midlands Specialised Commissioning Group Commissioning Policy for Hepatitis C Treatments
    This commissioning policy paper was produced for the treatment of patients with Hepatitis C in the East Midlands, with the aim of providing and ensuring equity, consistency and clarity in approach to treatment across the region. The document sets out the position of East Midlands Specialised Commissioning Group PCTs in respect of treatment for Hepatitis C for its current and future patients, outlining the treatment regimens for the various different genotypes of Hepatitis C using combination therapy (pegylated interferon alpha and weight-based ribavirin).
    East Midlands Jun 2009 Case study, Tools & Templates, Strategy & Planning PDF

Pages